Home

 

 

Latest Discussions

Member Spotlight

Latest Specialty News

  • A biomedical tool that tricks aggressive brain tumors such as glioblastoma into migrating into an external container rather than throughout the brain has been designated a "Breakthrough Device" by the U.S. Food and Drug Administration. Dubbed the Tumor Monorail, the device mimics the physical properties of the brain's white matter to entice aggressive tumors to migrate toward the exterior of the brain, where the migrating cells can be collected and removed. The purpose of the device is not to destroy the tumor, but to halt its lethal spread, making the disease more of a condition to manage than a death sentence.
  • Apply for Scholarship: The AAHPM/HPNA Annual Assembly In memory of longtime member and assistant editor of JOPON, Cindy Stutzer, MS RN and in collaboration with the Hospice and Palliative Nurse Association (HPNA), APHON is providing members with a scholarship opportunity to attend the AAHPM/HPNA Annual Assembly to further their education in hospice and palliative care. The Assembly takes place at the Hyatt Regency Orlando in Florida, March 13-16. The winner of the scholarship will then be reimbursed for their registration. Learn more and apply! Deadline is today – Feb. 14.
  • Nominations are now open for APHON leadership positions with service beginning in September 2019. In 2019 APHON members will vote for one Director-at-Large (three-year term) and two Nominating Committee members (three-year terms each). Candidates for Director-at-Large must be prepared to attend two board meetings per year. One board meeting is held at the APHON office in Chicago, IL (expenses paid by APHON), and one meeting is held in conjunction with the annual APHON conference. Candidates for Nominating Committee must be prepared to attend a yearly meeting at the annual conference. Visit the APHON website to learn more about serving APHON as a Director-at-Large or a member of the Nominating Committee. Deadline is tomorrow, Friday, Feb. 15.

APHON Events


Log in to see this information

Either the content you're seeking doesn't exist or it requires proper authentication before viewing.

Facebook Feed

Twitter Feed